ERBB2 and breast carcinoma: It has also been shown that dual blockage of CDK12/HER2 in HER2‐positive NST breast cancer results in reduced endocrine resistance and better response to anti‐HER2 therapy also in the metastatic setting [24, 25, 26, 27, 28].